Global health R&D at work in North Carolina
RTI International, in partnership with TB Alliance, is supporting development of new drugs for tuberculosis. One new drug therapy, PaMZ, promises to dramatically shorten and simplify treatment for multidrug-resistant tuberculosis (MDR-TB). Today people with MDR-TB face up to two years of treatment with only a 50 percent success rate. This game-changing therapy now in late-stage development is expected to decrease treatment to 6 months and reduce costs by 90 percent.